Jianjun Gao

Assistant Professor

The University of Texas MD Anderson Cancer Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (45)

Year:

2026

Year:

2025

Year:

2025

Background Sitravatinib, an oral multi-kinase inhibitor targeting VEGFR, TAM, and MET, has been shown to resensitize the tumor microenvironment to immune checkpoint inhibitors (ICI) by reducing immune-suppressive myeloid cells in metastatic clear cell RCC (ccRCC). ICI is the standard first-line (1L) treatment of metastatic ccRCC, and there is unmet need for improved treatment outcomes after progression on ICI. We hypothesized that sitravatinib plus nivolumab would revert an immunosuppressive tumor microenvironment (TME) to improve clinical outcomes. Methods In this investigator-initiated, phase II, multicenter trial (NCT04904302), patients with progressive metastatic ccRCC after 1-2 lines of treatment were enrolled into 3 cohorts: (1) 1L nivolumab + ipilimumab, (2) 1L pembrolizumab + axitinib, (3) prior cabozantinib or lenvatinib and ICI. Starting dose of sitravatinib was 100 mg PO daily and nivolumab was 480 mg IV every 4 weeks. The co-primary endpoints were objective response rate (ORR) and disease control rate (DCR) at 24 weeks. The study was designed to enroll 88 patients with an interim analysis for futility in each cohort using a BOP2 design, but it was terminated early due to discontinuation of sitravatinib development. Results Fourteen patients were enrolled with 2 in cohort A, 6 in cohort B, and 6 in cohort C. Across all cohorts, the ORR was 15.4% (2/13, 1 not evaluable) and DCR at 24 weeks was 35.7% (5/14). DCR at 24 months was 63% for Cohort A + B and 0% for Cohort C. Median progression free survival was 5.5 mo [95% CI 3.8—not reached (NR)], and median overall survival was 13.3 mo (95% CI 8.77—NR). Six patients (42.9%) experienced a grade 3-4 adverse event (AE) and 2 patients (14.3%) experienced an immune-mediated AE. Conclusion In this small phase 2 trial with limited sample size due to early termination, sitravatinib plus nivolumab demonstrated a manageable safety profile and produced modest clinical benefit. The observed responses occurred in patients who did not receive prior treatment with cabozantinib or lenvatinib. (ClinicalTrials.gov Identifier: NCT04904302).

Year:

2025

Supplementary Figure S3 Clinical courses of MRD+ cases and tumor expression profiles in MRD lesions. (A) The expression of potential therapeutic targets and genes of interest in the tumor region of sample 3A, the MRD sample from Pt-10. (B) The clinical course of the other three MRD+ cases, as represented by dynamic changes of serum CA-125 level, along with H&E staining, pathology annotations of tumor and non-tumor regions, as well as the expression of potential therapeutic targets and genes of interest in the MRD samples.

Year:

2025

Purpose: Minimal residual disease (MRD) after first-line treatment of advanced-stage ovarian cancer remains a long-standing barrier to cure. We investigated the prognostic and translational value of MRD detection by second-look laparoscopy (SLL) and ctDNA at the completion of first-line therapy. Experimental Design: Patients with high-grade epithelial ovarian cancer who had a complete clinical response to first-line therapy and underwent SLL and plasma collection for ctDNA were included. Progression-free survival (PFS) and overall survival (OS) were estimated based on MRD and clinicopathologic status. Spatial transcriptomics (GeoMx and Visium) and proteomics (CODEX) profiling were performed on serial samples from select patients. Results: Forty of 95 (42.1%) patients had surgically detected MRD, which was associated with worse PFS (median PFS 7.4 vs. 23.8 months; P P P = 0.013) in multivariable analysis. Among 44 patients who underwent SLL and had ctDNA testing, 34% (15/44) were ctDNA-positive, which was associated with worse PFS (6.4 vs. 28.1 months; P P = 0.008). We demonstrated the feasibility of spatial multiomics in studying MRD and their ability to provide hypothesis-generating observations, implicating the upregulation of the hypoxia signaling pathway, expression of multiple druggable targets ( CDK6 , GLS , MSLN , ERBB2 ), and immune exclusion in MRD lesions. Conclusions: Approximately half of patients in clinical remission after first-line therapy have assessable MRD, which can inform prognosis, therapeutic target discovery, and clinical trials.

Year:

2025

Supplementary Figure S4 Immune exclusion in the SLL sample 6B revealed by orthogonal spatial profiling. (A) CODEX profiling revealed two representative regions in the MRD sample (6B) of Pt-67. Region 1 located in the tumor margin where tumor cells interfaced with abundant CD8 T cells that demonstrated an exhausted state. This region was also enriched for interferon-stimulating signals. In contrast, region 2 represented tumor interior where very few CD8 T cells were observed. (B) Visium spatial profiling of the same sample as (A). CD8 T cell signals were detected in the tumor margin, which highly overlapped with the signals of immune checkpoint and interferon-stimulated genes.

Year:

2025

Supplementary Figure S2 Transcriptomic level comparisons of the tumor compartment between MRD and IDS samples using GeoMx data. (A) Volcano plot showing DEGs between the tumor compartment of MRD and IDS samples, with genes related to hypoxia signaling highlighted. (B) GSEA showing enriched pathways in the tumor compartment of MRD samples.

Year:

2025

Supplementary Figure S1 Clinical management of patients in the study cohort following SLL. *Many of these patients had the HRD assay performed retroactively on archival tissue and in this case, HRD status was not known in the upfront maintenance setting to guide therapy.

Year:

2025

Analysis of CD8+ cell infiltration at baseline in bone tumors and description of COMET analysis. A) Representative images captured by confocal microscope of CD8+ cell infiltration in bone tumors and quantification of CD8+ cell number; tumor (green, GFP), CD8+ cells (yellow), blood vessels (laminin, red), nuclei (blue, DAPI); dashed line, tumor edge; mean + SEM, n=3/group; dotted lines. B) Spatial definition of tumor edge; dashed line, tumor edge; dotted lines were draw at + 25 µm of distance from the tumor edge, that represents the tumor interface. C) A quantification of the % of CD8+ cells is shown, mean + SEM, n=3/group. D) Visual representation of experimental design (referred to Figure 4.). E, F) Representative images captured by confocal microscope of the distance (dotted line) between CD8+ cells (yellow) and the closest blood vessel (red, laminin) with quantification, mean + SEM, n=25-75/group. (F). G) Representation of step-by-step process of analysis of the immune infiltrate including tissue segmentation in VisioPharm. P values by one-way ANOVA with Tukey’s HSD post hoc test; p

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (42)

Matthew Campbell

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Yesim Gokmen-Polar

Associate Professor

Emory University

UNITED STATES
View details

Pavlos Msaouel

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Katherine Kurnit

Assistant Professor

University of Chicago Medicine

UNITED STATES
View details

Kaitlin J Basham

Assistant Professor

University of Utah

UNITED STATES
View details

Nizar M Tannir

Professor and Deputy Chair

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Daniel Frigo

Scientific Director of Research

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Mingyao Li

Professor of Biostatistics, Digital Pathology, Statistics & Data Science

University of Pennsylvania

UNITED STATES
View details

Roni Wilke

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Anil Sood

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Sanghoon Lee

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Amir Jazaeri

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Edwin Roger Parra

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Andrew Futreal

Chair and Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Eleonora Dondossola

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jeffrey How

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Yibo Dai

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Shannon Westin

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Paola A. Guerrero

Research Group Leader

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Gwyn Richardson

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Sangeeta Goswami

Associate Professor/ Joint Appointment

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jennifer A. Wargo

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Stephanie Watowich

Vivian L. Smith Distinguished Chair in Immunology

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Sreyashi Basu

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Sunil Badve

Vice Chair/ Professor

Emory University

UNITED STATES
View details

Dipen Maru

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Manoj Chelvanambi

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Pamela Soliman

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Cara Haymaker

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Xin Shelley Wang

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Nathaniel Wilson

Assistant Professor of Hematology and Medical Oncology

Winship Cancer Institute of Emory University

UNITED STATES
View details

Minetta Liu

Research Collaborator, Professor

Mayo Clinic

UNITED STATES
View details

Ying Yuan

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Kai Wucherpfennig

Professor and Department Chair

Dana-Farber Cancer Institute

UNITED STATES
View details

Alexander Lazar

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Ken Chen

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Humam Kadara

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Lulu Shang

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Linghua Wang

Executive Director & Head

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jared Burks

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Yinghong Wang

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

David Boruta

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details